|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
188,370,000 |
Market
Cap: |
16.70(B) |
Last
Volume: |
1,778,607 |
Avg
Vol: |
1,398,026 |
52
Week Range: |
$76.22 - $99 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : 811 |
Guru Rank Value : 0.9 |
Guru Occurances : 1 |
|
|
|
|
|
|
|
Company Profile BioMarin Pharmaceutical is a biotechnology company that develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Co.'s commercial products are Aldurazyme (laronidase) for Mucopolysaccharidosis I; Brineura (cerliponase alfa) for the treatment of late infantile neuronal ceroid lipofuscinosis type 2; Kuvan (sapropterin dihydrochloride) for the treatment of phenylketonuria; Naglazyme (galsulfase) the treatment of Mucopolysaccharidosis VI ; Palynziq (pegvaliase-pqpz) for adult patients with phenylketonuria; and Vimizim (elosulfase alpha) for the treatment of Mucopolysaccharidosis IV Type A.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
3,625 |
Total Buy Value |
$0 |
$0 |
$0 |
$314,469 |
Total People Bought |
0 |
0 |
0 |
1 |
Total Buy Transactions |
0 |
0 |
0 |
1 |
Total Shares Sold |
139,229 |
182,993 |
316,353 |
638,922 |
Total Sell Value |
$12,316,080 |
$16,513,389 |
$28,948,007 |
$60,375,372 |
Total People Sold |
5 |
5 |
6 |
8 |
Total Sell Transactions |
11 |
15 |
24 |
57 |
End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Bienaime Jean Jacques |
Chief Executive Officer |
|
2015-04-17 |
5 |
GD |
$0.00 |
$0 |
D/D |
500 |
228,254 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2015-04-01 |
4 |
AS |
$120.53 |
$422,590 |
D/D |
(3,506) |
251,251 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2015-04-01 |
4 |
AS |
$120.53 |
$2,717,546 |
I/I |
(22,546) |
33,258 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2015-04-01 |
4 |
OE |
$6.46 |
$145,647 |
I/I |
22,546 |
55,804 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2015-03-20 |
4 |
AS |
$126.40 |
$126,396 |
I/I |
(1,000) |
33,258 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2015-03-17 |
4 |
AS |
$124.87 |
$124,866 |
I/I |
(1,000) |
34,258 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2015-03-16 |
4 |
AS |
$123.48 |
$123,477 |
I/I |
(1,000) |
35,258 |
|
- |
|
Fuchs Henry J |
EVP, Chief Medical Officer |
|
2015-03-16 |
4 |
AS |
$123.57 |
$5,105,166 |
D/D |
(41,315) |
88,635 |
|
- |
|
Fuchs Henry J |
EVP, Chief Medical Officer |
|
2015-03-16 |
4 |
OE |
$21.51 |
$860,400 |
D/D |
40,000 |
129,950 |
|
- |
|
Mueller Brian |
VP, Corporate Controller |
|
2015-03-16 |
4 |
A |
$0.00 |
$0 |
D/D |
4,000 |
12,800 |
|
- |
|
Davis George Eric |
SVP, General Counsel |
|
2015-03-13 |
4 |
S |
$120.87 |
$1,813,002 |
D/D |
(15,000) |
73,846 |
|
- |
|
Davis George Eric |
SVP, General Counsel |
|
2015-03-13 |
4 |
OE |
$26.49 |
$556,239 |
D/D |
15,000 |
88,846 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2015-03-10 |
4 |
S |
$114.89 |
$232,201 |
I/I |
(2,021) |
36,258 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2015-03-09 |
4 |
S |
$112.12 |
$2,130,383 |
I/I |
(19,000) |
38,279 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2015-03-09 |
4 |
OE |
$12.99 |
$194,850 |
I/I |
15,000 |
57,279 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2015-03-05 |
4 |
S |
$113.70 |
$1,137,016 |
I/I |
(10,000) |
42,279 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2015-03-05 |
4 |
OE |
$12.99 |
$129,900 |
I/I |
10,000 |
52,279 |
|
- |
|
Baffi Robert |
EVP, Technical Operations |
|
2015-03-05 |
4 |
S |
$116.37 |
$1,635,091 |
D/D |
(14,051) |
109,700 |
|
- |
|
Baffi Robert |
EVP, Technical Operations |
|
2015-03-05 |
4 |
OE |
$14.39 |
$240,364 |
D/D |
14,051 |
123,751 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2015-03-04 |
4 |
AS |
$107.71 |
$98,660 |
I/I |
(916) |
42,279 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2015-03-04 |
4 |
OE |
$9.86 |
$4,930 |
I/I |
500 |
43,695 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2015-03-03 |
4 |
A |
$0.00 |
$0 |
D/D |
39,600 |
254,757 |
|
- |
|
Davis George Eric |
SVP, General Counsel |
|
2015-03-03 |
4 |
A |
$0.00 |
$0 |
D/D |
9,600 |
73,846 |
|
- |
|
Ajer Jeffrey Robert |
SVP, Chief Commercial Of |
|
2015-03-03 |
4 |
A |
$0.00 |
$0 |
D/D |
10,500 |
42,090 |
|
- |
|
Fuchs Henry J |
EVP, Chief Medical Officer |
|
2015-03-03 |
4 |
A |
$0.00 |
$0 |
D/D |
13,400 |
89,950 |
|
- |
|
1356 Records found
|
|
Page 1 of 55 |
|
|